610 related articles for article (PubMed ID: 16125529)
1. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
2. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular consequences of early-onset growth hormone excess.
Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
[TBL] [Abstract][Full Text] [Related]
4. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
[TBL] [Abstract][Full Text] [Related]
5. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
Serri O; Beauregard C; Hardy J
J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
[TBL] [Abstract][Full Text] [Related]
6. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
8. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Florimonte L; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1999 Jan; 84(1):17-23. PubMed ID: 9920056
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly.
Niculescu D; Purice M; Coculescu M
Pituitary; 2013 Jun; 16(2):168-74. PubMed ID: 22562529
[TBL] [Abstract][Full Text] [Related]
10. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.
Lombardi G; Colao A; Marzullo P; Biondi B; Palmieri E; Fazio S;
J Endocrinol Invest; 2002 Dec; 25(11):971-6. PubMed ID: 12553557
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels.
Yoshida T; Shimatsu A; Sakane N; Hizuka N; Horikawa R; Tanaka T
J Clin Endocrinol Metab; 1996 Jan; 81(1):310-3. PubMed ID: 8550769
[TBL] [Abstract][Full Text] [Related]
12. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
[TBL] [Abstract][Full Text] [Related]
13. The GH-IGF-I axis and the cardiovascular system: clinical implications.
Colao A
Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone, acromegaly, and heart failure: an intricate triangulation.
Saccà L; Napoli R; Cittadini A
Clin Endocrinol (Oxf); 2003 Dec; 59(6):660-71. PubMed ID: 14974906
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
[TBL] [Abstract][Full Text] [Related]
16. Cardiac effect of thyrotoxicosis in acromegaly.
Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A
J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177
[TBL] [Abstract][Full Text] [Related]
17. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects.
Colao A; Marzullo P; Spiezia S; Ferone D; Giaccio A; Cerbone G; Pivonello R; Di Somma C; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1986-91. PubMed ID: 10372698
[TBL] [Abstract][Full Text] [Related]
18. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
19. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
20. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
